OncoMatch/Clinical Trials/NCT07162506
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Is NCT07162506 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chemotherapy for esophageal cancer.
Treatment: Chemotherapy — This is a single-center, Phase II clinical study aiming to evaluate the efficacy, safety, and organ preservation feasibility of definitive concurrent chemoradiotherapy versus surgery in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) who achieve clinical complete response/partial response (cCR/PR) after neoadjuvant camrelizumab combined with chemotherapy. A total of 120 eligible subjects will be enrolled. Patients with cCR/PR after 2 cycles of induction chemoimmunotherapy (camrelizumab + nab-paclitaxel + carboplatin) will be grouped based on personal willing: the control group (n=60) will receive radical esophagectomy + mediastinal lymph node dissection; the experimental group (n=60) will receive definitive concurrent chemoradiotherapy (radiotherapy: 50.4 Gy/28f; chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles). All the patients will receive camrelizumab maintenance therapy (200mg q21d) up to 1 year.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III, IVA (8th AJCC)
clinically staged as Stage II - IVa (cT1N1-3M0, cT2-4aN0-3M0 before treatment; 8th AJCC)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy (camrelizumab) — neoadjuvant
achieve cCR/PR after 2 cycles of camrelizumab combined with nab-paclitaxel and carboplatin
Must have received: taxane (nab-paclitaxel) — neoadjuvant
achieve cCR/PR after 2 cycles of camrelizumab combined with nab-paclitaxel and carboplatin
Must have received: platinum-based chemotherapy (carboplatin) — neoadjuvant
achieve cCR/PR after 2 cycles of camrelizumab combined with nab-paclitaxel and carboplatin
Cannot have received: anti-PD-1 therapy
Exception: except for camrelizumab
Anti-PD-1 (except for camrelizumab) or anti-PD-L1 antibody therapy
Cannot have received: anti-PD-L1 therapy
Anti-PD-1 (except for camrelizumab) or anti-PD-L1 antibody therapy
Cannot have received: chemotherapy
chemotherapy
Cannot have received: radiation therapy
radiotherapy
Cannot have received: targeted therapy
targeted therapy
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L; Platelets ≥ 80×10^9/L; Hemoglobin ≥ 9g/dL; Serum albumin ≥ 2.8g/dL; INR and APTT ≤ 1.5× ULN (subjects on stable anticoagulation therapy with INR within expected therapeutic range can be screened)
Kidney function
Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL/min
Liver function
Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN
The function of major organs meets the following requirements: ... see full criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify